Immatics N.V. develops clinical-stage cancer immunotherapies built around T-cell receptor biology, with a stated focus on precision targeting of PRAME across solid tumors. News about IMTX most often covers clinical updates for PRAME-directed cell therapies and TCR bispecifics, including anzu-cel (anzutresgene autoleucel, IMA203), IMA203CD8, IMA402 and IMA401 MAGEA4/8. Company announcements also cover presentations at oncology meetings such as ASCO, AACR and ESMO, where Immatics reports safety, dose-escalation and anti-tumor activity data across melanoma, ovarian cancer, synovial sarcoma and other PRAME-positive cancers.
Recurring updates include financial results, business updates, collaboration activity, clinical and regulatory disclosures, leadership changes, shareholder voting matters and capital-structure disclosures for the Nasdaq-listed biotechnology company.
Immatics presented clinical proof-of-concept data for its TCER® IMA401 targeting MAGEA4/8 at ESMO 2024. The Phase 1 dose escalation trial showed initial anti-tumor activity and a manageable tolerability profile in heavily pre-treated patients with various solid tumors. Key findings include:
- Objective response rate (ORR) of 29% and disease control rate (DCR) of 53% in the efficacy population
- Durable responses lasting up to 13+ months
- Median terminal half-life of over two weeks, supporting q2w dosing
- Manageable safety profile with transient lymphopenia and mild to moderate CRS as most frequent treatment-related AEs
Immatics will regain full rights to IMA401 as Bristol Myers Squibb ends collaboration due to portfolio prioritization. The company plans to advance IMA401 further, with the next data update expected in 2025.
Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has announced an upcoming oral presentation at the 21st International Congress of the Society for Melanoma Research. The presentation will feature updated clinical data on the company's lead cell therapy candidate, ACTengine® IMA203, which targets PRAME in PD1-refractory metastatic melanoma.
The presentation is scheduled for October 11, 2024, from 8:00 to 8:20 am CDT, during the Plenary Session 1 on Developmental Immunotherapy. Dr. Martin Wermke from the University Hospital Dresden, Germany, will deliver the presentation titled 'ACTengine IMA203 TCR-T targeting PRAME in PD1-refractory metastatic melanoma – Clinical Update'.
Immatics N.V. (NASDAQ: IMTX) reported its Q2 2024 financial results and provided a business update. Key highlights include:
- ACTengine® IMA203 targeting PRAME showed a 55% confirmed objective response rate in 30 metastatic melanoma patients, with a median duration of response of 13.5 months.
- First Phase 1 data from TCER® IMA401 (MAGEA4/8) to be presented at ESMO Congress 2024.
- Cash position of $568.5 million as of June 30, 2024, funding operations into 2027.
- Q2 2024 revenue was $20.1 million, with a net loss of $19.3 million.
- Appointment of Alise Reicin M.D. to Board of Directors.
Immatics N.V. (NASDAQ: IMTX), a clinical-stage biopharmaceutical company focused on T cell-redirecting cancer immunotherapies, has appointed Alise Reicin, M.D., to its Board of Directors. Dr. Reicin, currently President and CEO of Tectonic Therapeutic, brings extensive experience in clinical development, including her role in the approval of Keytruda®. Her appointment comes as Immatics advances its pipeline of TCR-based cell therapy and bispecific product candidates.
Peter Chambré, Chairman of Immatics' Board, highlighted Dr. Reicin's expertise in facilitating the approval and launch of novel therapies. Dr. Reicin expressed enthusiasm for Immatics' potential, particularly noting the deep and durable responses from its lead cell therapy candidate, ACTengine® IMA203, in advanced metastatic melanoma patients. Her appointment continues through the Company's Annual General Meeting in 2025.
Immatics N.V. (NASDAQ: IMTX) has announced an upcoming oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The presentation will showcase the first proof-of-concept clinical data for TCER® IMA401, their next-generation, half-life extended TCR Bispecific molecule targeting MAGEA4/8.
The presentation, titled "Initial safety, pharmacokinetics, and anti-tumor activity data of TCER IMA401, a MAGEA4/8-directed half-life extended TCR Bispecific, in Phase 1 dose escalation," will be delivered by Dr. Martin Wermke from University Hospital Dresden, Germany. It is scheduled for September 16, 2024, at 11:25 CEST in the Granada Auditorium - Hall 6, as part of the Investigational Immunotherapy session.
Full abstracts will be available on the ESMO website on September 9, 2024, at 00:05 CEST.
Immatics (NASDAQ: IMTX) reported its Q1 2024 financial results and provided a business update, including clinical data from their ongoing Phase 1 trial of ACTengine® IMA203 targeting PRAME. The trial showed a 55% confirmed objective response rate in heavily pre-treated metastatic melanoma patients, with tumor shrinkage in 87% and a median response duration of 13.5 months. IMA203 maintained a favorable safety profile. A Phase 2/3 trial is planned for 2024.
The company also completed a $201.5 million public offering in January 2024, ending the quarter with $609.7 million in cash and equivalents, funding operations into 2027. Q1 2024 revenues were $32.8 million, largely due to a terminated collaboration, while net loss narrowed to $3.4 million from $21.3 million in Q1 2023. Upcoming milestones include updates on IMA203, IMA203CD8, and TCER® programs in 2H 2024.
Summary not available.
Summary not available.
Summary not available.
Summary not available.